Incyte's Tafasitamab Trial Shows Promising Results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 27 2026
0mins
Source: CNBC
Incyte Corp's stock price fell by 5.02% today, crossing below the 5-day SMA, amid a broader market decline with the Nasdaq-100 down 0.80% and the S&P 500 down 0.11%.
The decline in Incyte's stock comes despite the positive news regarding its tafasitamab trial, which achieved key milestones in treating diffuse large B-cell lymphoma (DLBCL). The trial met its primary endpoint, indicating significant potential efficacy, and Incyte plans to file a supplemental Biologics License Application for tafasitamab in the first half of 2026. However, analyst William Blair notes that the competitive landscape may limit the drug's market potential due to several competing therapies currently in Phase 3 trials.
This situation highlights the challenges Incyte faces in capitalizing on its promising trial results, as the stock's performance is affected by broader market trends and competitive pressures in the oncology space.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy INCY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on INCY
Wall Street analysts forecast INCY stock price to rise
19 Analyst Rating
9 Buy
9 Hold
1 Sell
Moderate Buy
Current: 97.410
Low
73.00
Averages
100.31
High
125.00
Current: 97.410
Low
73.00
Averages
100.31
High
125.00
About INCY
Incyte Corporation is a biopharmaceutical company, which is focused on the discovery, development, and commercialization of therapeutics. The Company operates in two therapeutic areas. One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. Its other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise are comprised of six products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib), ICLUSIG (ponatinib), NIKTIMVO (axatilimab-csfr), and ZYNYZ (retifanlimab-dlwr), as well as numerous clinical development programs. The Company's pipeline also includes two first-in-class small molecule antagonist of Mas-related G protein-coupled receptor (MRGPRX2) and INCB000547, an oral MRGPRX4 antagonist.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Incyte and Genesis Expand AI Drug Discovery Partnership
- Partnership Expansion: Incyte and Genesis Molecular AI announced the expansion of their AI drug discovery partnership, leveraging Genesis' GEMS platform to accelerate the development of new small-molecule medicines, highlighting their deep collaboration potential in innovative drug development.
- Financial Commitment: Under the agreement, Incyte will share its proprietary experimental data to train Genesis' AI models, with Genesis receiving a total of $120 million, including $80 million in upfront cash and $40 million in equity investment, ensuring ongoing research and development funding.
- New Drug Targets: The collaboration adds at least five new drug targets, granting Incyte exclusive rights to develop and commercialize any resulting drug products, indicating a strategic advantage in new drug development.
- Potential Earnings: Genesis can earn up to $232 million per program in milestone payments, with total potential value exceeding $1 billion, along with royalties on future approved drugs, showcasing the long-term profitability potential of this partnership.
See More
Incyte Grants Equity Inducement Awards to New CFO Suketu Upadhyay
- Executive Appointment: Incyte Corporation has appointed Suketu Upadhyay as the new Executive Vice President and Chief Financial Officer, aiming to leverage his extensive financial management experience to drive strategic growth.
- Equity Inducement Awards: Under the 2024 Inducement Stock Incentive Plan, Upadhyay received stock options for 38,429 shares, restricted stock units (RSUs) for 26,343 shares, and performance shares for 13,171 shares, reflecting the company's high expectations for his future contributions.
- Options Details: The stock options have an exercise price of $97.14 per share, equal to the closing price on the grant date, with 25% vesting on the one-year anniversary and the remainder vesting in 36 equal monthly installments, ensuring Upadhyay's continued service.
- Performance Share Incentives: The performance shares are tied to the company's relative total shareholder return (TSR) performance, with a target range of 0-200%, incentivizing Upadhyay to drive company performance over the next three years.
See More
NIKTIMVO Approved in Australia for Chronic Graft-Versus-Host Disease Treatment
- First Approval: NIKTIMVO (axatilimab) has been approved in Australia for the treatment of chronic graft-versus-host disease (cGVHD), becoming the first anti-CSF-1R antibody to receive marketing authorization in the country, marking a significant step in its global rollout.
- Clinical Trial Results: In a study involving 241 patients who had received at least two prior lines of systemic therapy, NIKTIMVO demonstrated an overall response rate of 74%, with 60% of patients maintaining their response at 12 months, indicating its efficacy and potential long-term benefits in treating cGVHD.
- Market Demand: Approximately 600 allogeneic stem cell transplants are performed annually in Australia, with cGVHD affecting 40-50% of recipients; the approval of NIKTIMVO provides a new treatment option for these patients, addressing the urgent need for effective therapies in the market.
- Strategic Partnership: Specialised Therapeutics has entered into an exclusive partnership with Incyte to commercialize NIKTIMVO in Australia, New Zealand, and Singapore, further solidifying its market position in the Asia-Pacific region.
See More
Incyte Receives FDA Approval for Jakafi XR
- FDA Approval: Incyte announced that its Jakafi XR (ruxolitinib) extended-release tablets have received FDA approval, marking a significant advancement in the treatment of blood disorders for the company.
- Expanded Indications: The drug is indicated for adults with intermediate- or high-risk myelofibrosis, those with polycythemia vera who have had inadequate responses to or are intolerant of hydroxyurea, and patients aged 12 and older with steroid-refractory acute or chronic graft-versus-host disease, showcasing its broad clinical application potential.
- Clinical Study Support: The approval was based on a clinical study demonstrating that a single 55 mg Jakafi XR tablet taken once daily is bioequivalent to a 25 mg immediate-release Jakafi tablet taken twice daily, simplifying the dosing regimen and enhancing patient adherence to treatment.
- Market Launch Date: Jakafi XR will be available for pharmacy orders starting May 8, which is expected to generate new revenue streams for Incyte while strengthening its position in the competitive oncology drug market.
See More
FDA Approves Jakafi XR for Myelofibrosis and GVHD Treatment
- FDA Approval: Incyte announced that its Jakafi XR (ruxolitinib) has received FDA approval for the treatment of intermediate- or high-risk myelofibrosis (MF) and polycythemia vera (PV) patients who have had an inadequate response to hydroxyurea, reinforcing the company's leadership in hematology.
- Dosing Advantage: Jakafi XR is a once-daily extended-release formulation that provides comparable drug exposure to the twice-daily immediate-release formulation, offering a more convenient dosing option aimed at improving patient adherence and quality of life.
- Clinical Study Support: The FDA approval is based on clinical study results demonstrating that a single 55 mg Jakafi XR tablet taken once daily is bioequivalent to a 25 mg Jakafi tablet taken twice daily, indicating potential for similar clinical benefits.
- Patient Support Program: Incyte has launched the IncyteCARES program, providing personalized support, including financial assistance and educational resources, to eligible patients, aiming to eliminate barriers to access and further solidify its market position.
See More
Incyte Reports Strong Q1 2026 Earnings with Strategic Growth Plans
- Significant Sales Growth: Incyte reported net sales of $1.1 billion in Q1 2026, reflecting a 20% year-over-year increase, indicating strong demand across its hematology, oncology, and immunology product portfolio, which enhances overall performance.
- New Product Launch Plans: Management anticipates launching four new products over the next 12 months, including Jakafi XR and Opzelura, which will further strengthen the company's market competitiveness and drive revenue growth, particularly in the European market.
- Leadership Changes: Incyte appointed Suky Upadhyay as Chief Financial Officer and reorganized its U.S. commercial team to establish consistent standards and enterprise-level capabilities, aiming to prepare for product launches in 2026 and enhance operational efficiency.
- Reaffirmed Financial Guidance: The company reaffirmed its total net sales guidance for 2026 at $4.77 billion to $4.94 billion, with Jakafi sales expectations of $3.22 billion to $3.27 billion, demonstrating management's confidence in future performance and market demand.
See More
Incyte and Genesis Expand AI Drug Discovery Partnership
- Partnership Expansion: Incyte and Genesis Molecular AI announced the expansion of their AI drug discovery partnership, leveraging Genesis' GEMS platform to accelerate the development of new small-molecule medicines, highlighting their deep collaboration potential in innovative drug development.
- Financial Commitment: Under the agreement, Incyte will share its proprietary experimental data to train Genesis' AI models, with Genesis receiving a total of $120 million, including $80 million in upfront cash and $40 million in equity investment, ensuring ongoing research and development funding.
- New Drug Targets: The collaboration adds at least five new drug targets, granting Incyte exclusive rights to develop and commercialize any resulting drug products, indicating a strategic advantage in new drug development.
- Potential Earnings: Genesis can earn up to $232 million per program in milestone payments, with total potential value exceeding $1 billion, along with royalties on future approved drugs, showcasing the long-term profitability potential of this partnership.
See More
Incyte Grants Equity Inducement Awards to New CFO Suketu Upadhyay
- Executive Appointment: Incyte Corporation has appointed Suketu Upadhyay as the new Executive Vice President and Chief Financial Officer, aiming to leverage his extensive financial management experience to drive strategic growth.
- Equity Inducement Awards: Under the 2024 Inducement Stock Incentive Plan, Upadhyay received stock options for 38,429 shares, restricted stock units (RSUs) for 26,343 shares, and performance shares for 13,171 shares, reflecting the company's high expectations for his future contributions.
- Options Details: The stock options have an exercise price of $97.14 per share, equal to the closing price on the grant date, with 25% vesting on the one-year anniversary and the remainder vesting in 36 equal monthly installments, ensuring Upadhyay's continued service.
- Performance Share Incentives: The performance shares are tied to the company's relative total shareholder return (TSR) performance, with a target range of 0-200%, incentivizing Upadhyay to drive company performance over the next three years.
See More
NIKTIMVO Approved in Australia for Chronic Graft-Versus-Host Disease Treatment
- First Approval: NIKTIMVO (axatilimab) has been approved in Australia for the treatment of chronic graft-versus-host disease (cGVHD), becoming the first anti-CSF-1R antibody to receive marketing authorization in the country, marking a significant step in its global rollout.
- Clinical Trial Results: In a study involving 241 patients who had received at least two prior lines of systemic therapy, NIKTIMVO demonstrated an overall response rate of 74%, with 60% of patients maintaining their response at 12 months, indicating its efficacy and potential long-term benefits in treating cGVHD.
- Market Demand: Approximately 600 allogeneic stem cell transplants are performed annually in Australia, with cGVHD affecting 40-50% of recipients; the approval of NIKTIMVO provides a new treatment option for these patients, addressing the urgent need for effective therapies in the market.
- Strategic Partnership: Specialised Therapeutics has entered into an exclusive partnership with Incyte to commercialize NIKTIMVO in Australia, New Zealand, and Singapore, further solidifying its market position in the Asia-Pacific region.
See More
Incyte Receives FDA Approval for Jakafi XR
- FDA Approval: Incyte announced that its Jakafi XR (ruxolitinib) extended-release tablets have received FDA approval, marking a significant advancement in the treatment of blood disorders for the company.
- Expanded Indications: The drug is indicated for adults with intermediate- or high-risk myelofibrosis, those with polycythemia vera who have had inadequate responses to or are intolerant of hydroxyurea, and patients aged 12 and older with steroid-refractory acute or chronic graft-versus-host disease, showcasing its broad clinical application potential.
- Clinical Study Support: The approval was based on a clinical study demonstrating that a single 55 mg Jakafi XR tablet taken once daily is bioequivalent to a 25 mg immediate-release Jakafi tablet taken twice daily, simplifying the dosing regimen and enhancing patient adherence to treatment.
- Market Launch Date: Jakafi XR will be available for pharmacy orders starting May 8, which is expected to generate new revenue streams for Incyte while strengthening its position in the competitive oncology drug market.
See More
FDA Approves Jakafi XR for Myelofibrosis and GVHD Treatment
- FDA Approval: Incyte announced that its Jakafi XR (ruxolitinib) has received FDA approval for the treatment of intermediate- or high-risk myelofibrosis (MF) and polycythemia vera (PV) patients who have had an inadequate response to hydroxyurea, reinforcing the company's leadership in hematology.
- Dosing Advantage: Jakafi XR is a once-daily extended-release formulation that provides comparable drug exposure to the twice-daily immediate-release formulation, offering a more convenient dosing option aimed at improving patient adherence and quality of life.
- Clinical Study Support: The FDA approval is based on clinical study results demonstrating that a single 55 mg Jakafi XR tablet taken once daily is bioequivalent to a 25 mg Jakafi tablet taken twice daily, indicating potential for similar clinical benefits.
- Patient Support Program: Incyte has launched the IncyteCARES program, providing personalized support, including financial assistance and educational resources, to eligible patients, aiming to eliminate barriers to access and further solidify its market position.
See More
Incyte Reports Strong Q1 2026 Earnings with Strategic Growth Plans
- Significant Sales Growth: Incyte reported net sales of $1.1 billion in Q1 2026, reflecting a 20% year-over-year increase, indicating strong demand across its hematology, oncology, and immunology product portfolio, which enhances overall performance.
- New Product Launch Plans: Management anticipates launching four new products over the next 12 months, including Jakafi XR and Opzelura, which will further strengthen the company's market competitiveness and drive revenue growth, particularly in the European market.
- Leadership Changes: Incyte appointed Suky Upadhyay as Chief Financial Officer and reorganized its U.S. commercial team to establish consistent standards and enterprise-level capabilities, aiming to prepare for product launches in 2026 and enhance operational efficiency.
- Reaffirmed Financial Guidance: The company reaffirmed its total net sales guidance for 2026 at $4.77 billion to $4.94 billion, with Jakafi sales expectations of $3.22 billion to $3.27 billion, demonstrating management's confidence in future performance and market demand.
See More
